Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alvogen to acquire Russia-based Omega Bittner
Working with well-established and recognized brands in Russia including Lactacyd, Aflubin and Paranit, the firm focuses on a targeted portfolio of over-the-counter drugs in categories such as women’s
Working with well-established and recognized brands in Russia including Lactacyd, Aflubin and Paranit, the firm focuses on a targeted portfolio of over-the-counter drugs in categories such as women’s
The Principal Investigator is Dr. James D. Blanchard, Principal Scientist, Preclinical Development at Aradigm. Professor Luiz Bermudez at Oregon State University, Corvallis, will lead the laboratory research as
H3B-8800, which is a potent, selective and orally bioavailable small molecule modulator of wild-type and mutant SF3b complexes, is currently in Phase 1 clinical trials. “Receiving the orphan
Unlike existing European commercialization options that require innovator companies to either invest significant resources to build their own infrastructure, or to sign away rights and value to a
Other partners include the Cell and Gene Therapy Catapult, Stratophase and Synthace, and the collaboration is co-funded by Innovate UK. The aim of the collaboration is to explore
New investors include Sofinnova, Vivo Capital, F-Prime Capital Partners, certain investment funds advised by Clough Capital Partners L.P., and venBio Select. Existing investors Morningside Ventures, Cormorant Asset Management,
Gilead filed the NDA for BIC/FTC/TAF with a Priority Review voucher on June 12, 2017, and FDA has set a target action date under the Prescription Drug User
"We are pleased that the FDA has granted orphan-drug designation for cobitolimod for treatment of ulcerative colitis in children, which may provide seven years of market exclusivity in
General agreement was reached with the FDA on the design and key elements for HTX-011’s Phase 3 program that will be required to support a New Drug Application
Mylan’s Chief Commercial Officer Tony Mauro said, “Mylan has a strong and sustained commitment to expanding access to treatment for HIV/AIDS and other diseases around the world, and